This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1. (Original) A method for treating arteriosclerosis in a mammal comprising administering an effective dose of one or more of the following primary agents to a mammal in need thereof:

a) acetaminophen;

b) a pharmaceutically acceptable salt of acetaminophen;

c) a pharmaceutically acceptable isomer of acetaminophen;

d) a pharmaceutically acceptable ester of acetaminophen;

e) a pharmaceutically acceptable ether of acetaminophen;

f) a prodrug of acetaminophen; or

g) mixtures thereof.

Claim 2. (Original) The method of claim 1 wherein the amount of acetaminophen in the dose is greater than or equal to about 0.14 mg/kg of body mass of the mammal and is less than or equal to about 57 mg/kg of body mass of the mammal.

Claim 3. (Original) The method of claim 2, wherein the dose further comprises an effective amount of a secondary agent for the treatment of arteriosclerosis or coronary disease selected from the group consisting of cholesterol lowering agents, antioxidants, antiplatelet agents, cholesterol-absorption inhibitors, and mixtures thereof.

Claim 4. (Previously Presented) The method of claim 3 wherein the cholesterol-lowering agents are selected from the group consisting of statins, fibrates, niacin, and mixtures thereof.

Claim 5. (Original) The method of claim 3 wherein the antioxidant agents are selected from the group consisting of vitamin E, vitamin C, and mixtures thereof.

Claim 6. (Original) The method of claim 3 wherein the antiplatelet agents are selected from aspirin, IIaIIIb inhibitors, and mixtures thereof.

Claim 7. (Original) The method of claim 3 wherein the cholesterol-absorption inhibitors include stanol fatty acid esters, soy, and derivatives and mixtures thereof.

Claim 8. (Original) The method of claim 3 wherein the second active ingredient is a statin.

Claim 9. (Original) The method of claim 3 wherein the second active ingredient is atorvastatin.

Claim 10. (Original) A method for treating atherosclerosis in a mammal comprising administering an effective dose of one or more of the following primary agents to a mammal in need thereof:

a) acetaminophen;

b) a pharmaceutically acceptable salt of acetaminophen;

c) a pharmaceutically acceptable isomer of acetaminophen;

d) a pharmaceutically acceptable ester of acetaminophen;

e) a pharmaceutically acceptable ether of acetaminophen;

f) a prodrug of acetaminophen; or

g) mixtures thereof.

Claim 11. (Original) The method of claim 10 wherein the amount of acetaminophen in the dose is greater than or equal to about 0.14 mg/kg of body mass of the mammal and is less than or equal to about 57 mg/kg of body mass of the mammal.

Claim 12. (Original) The method of claim 10, wherein the dose further comprises an effective amount of a secondary agent for the treatment of atherosclerosis selected from the group consisting of cholesterol lowering agents, antioxidants, antiplatelets, cholesterol-absorption inhibitors, and mixtures thereof.

Claim 13. (Previously Presented) The method of claim 12 wherein the cholesterol lowering agents are selected from the group consisting of statins, fibrates, niacin, and mixtures thereof.

Claim 14. (Original) The method of claim 12 wherein the antioxidant agents are selected from the group consisting of vitamin E, vitamin C, and mixtures thereof.

Claim 15. (Original) The method of claim 12 wherein the antiplatelet agents are selected from the group consisting of aspirin, IIaIIIb inhibitors, and mixtures thereof.

Claim 16 (Original) The method of claim 12 wherein the cholesterol-absorption inhibitors are selected from the group consisting of stanol fatty acid esters, soy, and derivatives and mixtures thereof.

Claim 17. (Original) The method of claim 12 wherein the secondary agent is a statin.

Claim 18. (Original) The method of claim 12 wherein the secondary agent is atorvastatin.

Claim 19 - 26. (Cancelled)